Hi, everyone. Good morning. Welcome to the 2026 Jefferies Healthcare Conference. It's my pleasure to welcome Eric Easom, CEO of AN2 Therapeutics. Thank you.
All right. Thank you very much. I'll be making certain forward-looking statements, so I wanted to make sure that that was known. To introduce AN2 Therapeutics. We are a boron chemistry platform-based company, and we have a strong clinical pipeline with three clinical proof of concept studies that are either ongoing or very close to starting in the next few weeks. We've got three of those. Our lead program is in hematology for polycythemia vera, or PV. I'll talk a lot more about that in this session. We also have two other projects for NTM, nontuberculous mycobacteria lung disease, targeting Mycobacterium abscessus, as well as Chagas disease. These are all proof of concept. They're novel. Two of these indications have no FDA-approved drugs, so we're very excited about the potential of these to help patients.
Near-term catalyst, we've got a very catalyst-rich 2027, and we've got all three of these will be reading out. Nearest term will be the polycythemia vera trial, and that we'll see starting as soon as the first quarter and throughout 2027. We also have a robust research pipeline, or R&D pipeline, that has a couple of development compounds that we've recently announced in oncology for ENPP1, and then most recently for hypophosphatasia, oral ENPP1 inhibitor that we're also excited. We've got a lot going on and a very productive boron platform here. Just to look at it in kind of a traditional pipeline sense. This shows the three lead compounds, but the main point I wanted to make here is that we're a platform company, and we follow biology. We've really expanded our focus from originally we were more focused on infectious diseases.
Now we have a very robust hematology and oncology pipeline with a very unique chemistry approach to it. We've got a strong infectious diseases pipeline with products that address high unmet needs and also have high commercial potential. Recently, as I mentioned, we have a rare bone disorder project in hypophosphatasia that we're very excited about. Something that's near and dear to us as a company that kind of sets us uniquely apart is we've been involved in global health from our earlier Anacor days up to AN2, and so we have a number of projects there. We've discovered probably 15 compounds for infectious diseases, for those who don't know us, including tuberculosis, malaria, lots of major global health problems. We're very supportive of doing that with non-dilutive funding from Gates Foundation and governments and so forth.
I think the real interest near term is inflection points and value creation in terms of phase II readouts. As I mentioned, we have three proof of concept readouts. All three of these, I think, are significant value inflection points for us as a company and really to prove out these compounds. We have multiple shots on goal, if you will. PV being the first of those. Polycythemia vera, we have phase II. We are going to initiate the phase II and have first patient dosed this year. This study is starting imminently. We will have the first kind of safety read of the data in the first quarter, and then throughout 2027, we will have efficacy data. That is an open-label trial, and I will talk a lot more in detail about that.
This is a once-daily oral red cell targeted therapy for PV, which is a highly sought profile compared to a lot of injectables and off target. Chagas disease too, and I will talk more about this, but we have a potential oral cure for this disease. Currently, the therapy available is not great, and so we really are excited about that. The disease affects 10 million people, 300,000 of which or more live in the U.S. This is a kind of an unknown disease to many people, but 10 million people have parasites in their heart. It is a silent killer, and it is a major health, unaddressed health issue. NTM is Mycobacterium abscessus. This is one where there is, again, like Chagas, there is no FDA-approved drugs for Mycobacterium abscessus. There are 15,000 patients in the U.S., and I will talk more about that.
We will have data on all three of those in 2027. It is lots of data inflection points coming in our near future. Our earlier pipeline, we have three exciting programs, and these will be making further development into clinical trials in late 2027 and forward. A lot more to come on those. All right. We want to spend a lot of time on polycythemia vera. This is a Our compound is epetraborole. It is in phase II, starting imminently, as I mentioned. It is oral, and it is red cell targeting. The real profile, I think, that is highly sought is a once-a-day oral therapy. We have vast amounts of clinical and preclinical data in non-PV patients showing the profile of red cell targeting, hematocrit reduction, which is exactly what you want with this, and selectivity without having lots of off-target activity around that.
We will have data throughout 2027. This is really the top priority, I think, in the near term for us as a company. Polycythemia vera, this is a disease where there is an overproduction of red blood cells, which leads to kind of a thickening or higher viscosity in your blood and a high risk of thrombotic events for patients with this. The primary treatment for this, you want to keep hematocrit below 45% and keep it in normal. These patients have super high hematocrit, so they have more red blood cells and less room for the cells to flow throughout the body. Currently, the primary treatment is phlebotomies. For a lifetime, you have to get a phlebotomy. In many patients, it is every other month, every month. You can imagine using therapeutic bloodletting essentially as your therapy, and low-dose aspirin to manage platelets.
There also are cytoreductive agents, but these have lots of off-target activities. They are injectables, other non-desirable features. The idea is to have a red cell targeting oral therapy that does not have a lot of side effects, and that is what we believe we have the potential for and we are going to be testing. I mentioned lots of clinical data. I just highlight one here. This was from a compound that we, this is epetraborole, we studied in a phase II/III nontuberculous mycobacteria lung disease trial. As you can see, our drug on top of an optimized background regimen of multi-antibiotics had a clear effect on hematocrit lowering. It is almost like the perfect step function, if you will.
It goes down over the first four to eight weeks, then it plateaus, and there is a compensatory action going, and it maintains that, and then as soon as you take drug off, it returns to baseline. This is very reproducible across, we have run more than 10 clinical trials and see the same phenotype, red cell targeting agent. We also see a very well-tolerated profile, and we have seen it in preclinical. We have done lots of NHP studies to also show this and look at PK/PD, et cetera. We have got lots of non-PV data. The real question for us is, will this translate to patients with polycythemia vera? Which we think it will. This just shows kind of the off-target effect. Essentially, it has absolutely no effect on white blood cells and platelets. They stay within normal range and very minor deviations.
This is unique in the fact that it is oral and does not have that, makes it very red cell specific, which is the exciting part of the profile. In terms of clinical trial, I mentioned we are going to be starting our trial in PV this year. We will be dosing the first patient sometime in the coming weeks, and then we will have a sentinel cohort. There is going to be initial 10 patients at a very low dose in a sentinel, just because we have never dosed a PV patient to see if we see all the right safety features and kind of phenotype, but it is mainly a safety readout, and that will happen in the first quarter.
That is the planned timeline for when we will read out that, and then they will go straight into this part one, which is all this is open label, so we will be able to see these data in real time. The dose titration will start with a fairly low dose and then allow on a per-patient basis for the dose to be escalated over a long enough period that we can really show the primary purpose of this, which is to reduce the need for therapeutic phlebotomies. That is really exciting. We will start having patients hit the 20-week mark sometime around mid-year, and we will do data cuts. We are not going to wait until we have all 75 to release data. We will have early readouts and then throughout 2027 on that.
There is a part two, which will then randomize patients off of therapy. We think you will see them go back out of control with phlebotomy only, and then those who stay on drug. That will be a double-blinded. Really, the proof of concept is part one, and that is the major question that we are trying to answer with this. We will be measuring lots of other parameters along the way and give updates on that. Okay, so that is PV. Mycobacterium abscessus. Again, this is no approved therapies by the U.S. FDA for this. Currently, it is all off-label, decades-old antibiotics. There are 15,000 in the U.S., 50,000 if you include Japan and Europe, so major markets here. It is a rare disease that really causes a high five-year mortality. Your lungs become fibrotic.
You have a lot of cavities and kind of a fibrosis of the lung, essentially. It is a bacteria that is related to Mycobacterium tuberculosis, but quite different and rare. Basically, the treatment for patients now that they have to contemplate is they go on multiple IV-only antibiotics daily for months and years. You can imagine, this is like chemotherapy. They are taking imipenem, they are taking amikacin. These are not for the faint of heart drugs that cause hearing loss, lots of other side effects that make it very demanding for patients to do that on a daily basis. Imagine. It is like old-time chemotherapy, and they take oral antibiotics. That is the situation. What we are really There has not been a lot of focus on this, but we have an oral therapeutic, epetraborole.
This is the same drug as SPV and the primary initial indication that we were going after. This is a novel oral leucyl-tRNA synthetase that is enabled by our boron chemistry. Lots of companies have tried to hit this target. Boron allows that to happen. It is completely novel. It is oral. We have worked on this target for tuberculosis. We licensed a compound to GSK, which is in clinical trials. We know a lot about this target and about the potential of an oral therapeutic. It looks incredibly good in preclinical animal models, and we are super excited. We have a phase II program that is an IIT being run by Kevin Winthrop, who is one of the leading KOLs in the entire space, and 15 other sites across all the top KOLs in the United States.
It is a multi-center phase II IIT run by Kevin with these different sites. We will have a readout on that in late 2027, and it is a significant inflection point, we believe, for our program. Then we have a program in Chagas disease. This is something that many people have never heard of. You get bitten by a so-called kissing bug at night, usually while you are sleeping, in the face. Takes a blood meal and causes parasites, much like you have probably heard of malaria or something. There are, this is the shocker, 10 million people with parasites, and they go into your muscle and your heart muscle, and that is where the problem is. This is why I got into this global health field, and this is one that affects people in all countries, including the United States.
There's 300,000 patients in the U.S., but 10 million throughout Latin America and around the world. It's shocking that we don't have a drug, and it's a silent killer. About 30% of patients develop heart failure, and you just drop dead one day of an aortic aneurysm or something because it basically causes scarring in your heart muscle. I don't think anybody wants parasites in their heart or anywhere in their body. They live there for decades, for your life, unless you treat it. We have a drug. This is an area that really sets us apart. It's an oral 28-day therapy, and we believe it has a curative profile. We've tested it in three distinct monkey or NHP models in the state of Texas, where the kissing bug resides in the U.S., infected kissing bugs.
We have no idea about the transmission in the U.S., but it's all throughout Latin America. These monkeys get infected in outdoor environments in the U.S., and we treat them and we cure them. It's about as strong of a rationale for technical success as you could possibly have going into phase II, is have that monkey data who's infected by a kissing bug, and it's a natural infection within monkeys, and we can do that. We'll have top line. We're starting a phase II trial in Bolivia, which has the highest incidence of Chagas in the world. About 8% of Bolivians have Chagas. Some communities, it's close to 100%. It'll be fast to enroll because there's millions of patients in Latin America, and they're easy to find. We'll be able to have top-line data next year. Quite excited about that.
There won't be another company here talking about Chagas, I don't think. It really is unique. Then we have a burgeoning pipeline of earlier stage projects. This again, we do boron chemistry. We're very adept at it. We've been doing it for 20 years, previously at Anacor, or we call it AN1 affectionately, and now we're AN2, which is where we get our name from. We have a newly announced program, which is an oral ENPP1 inhibitor for hypophosphatasia. This is a rare bone disorder, and really, it can be fatal at birth. Young infants can't form rib cages or bone in the worst of cases, and then they have various variants of genetic mutations that come up in life, and then there's a bigger market in the adult space. What I'm showing here is just some early data.
We just announced a preclinical candidate. We've selected a candidate. We made close to 1,000 analogs and really optimized for HPP in terms of potency, PK, off-target activity, et cetera. We think we have best-of-class profile in this. These data, if you're trying to read, it's kind of hard to read and little, but this is a mouse knockout model where they're completely forced into an HPP model, and we basically are showing that we're no different than. We're significantly better than the knockout model. Those mice don't survive much longer than a couple of weeks. Their bones don't grow. We have some really interesting bone pictures we could show you if we had more time, but it's really dramatic. We're similar to wild-type mice. There's no difference between our drug and wild type.
And we also compare it to the gold standard here, which is STRENSIQ, which is an injectable therapy that treats these patients now. It is an enzyme replacement. It is quite a large market, Alexion, AstraZeneca. But having an oral treatment, STRENSIQ is injectable three to 6x a week for children and adults for lifetime, and it is really not conducive for once children get old enough to take an oral solution, an oral medication that could address this, and particularly in children, adults, teenagers. So we think it is a huge opportunity to have an oral that addresses the bone issue. ENPP1 also has interesting biology. This is where we initially started on this target, which is in oncology.
So it is an immuno-oncology agent that essentially turns cold tumors that are not recognized by the immune system, the cancer hijacks that signaling pathway, into a Turns on, makes cold tumors hot, basically, where your immune system will help fight against that. So this pathway, STING pathway and STING agonists have a terrible reputation because many, five years ago or so, lots of companies were going after STING agonists. They had to inject tumors, they had terrible drug-like properties, and so forth. So this gets around all of that and does it through turning on the body's innate immune system. So, very excited about that program, and it is in preclinical. There recently was some interesting data. So there is a company in front of us called Riboscience that is doing the first phase II in colorectal cancer, and they had data at ESMO that is very exciting.
So we again think the boron is perfect for this target. It binds well as a warhead, and we can build it very specific and potent compared to other chemistries that are needed to hit this target. And we think ultimately we will have an advantage with the boron chemistry. And then lastly, we have a PI3 kinase alpha project. This is a very busy area. We view it as kind of three generations of compounds. So there is kind of first generation, which is alpelisib that hits wild type and mutants equally as potent. And the issue with that is lots of patients develop hyperglycemia, and they cannot tolerate it for very long. So the second generations, these are the Relays of the world that really have an exciting compound.
They are very kinase selective, so they separate, they are much more potent against kinase than they are wild type. It is about tenfold. But they have almost no selectivity over helical, which is about half of the mutants. And so now the third generation compounds, which would be highlighted, are equally potent again, or are potent against the kinase and helical, but spares the wild type. So they are true pan-mutant selective compounds. And the highlighted compound, I would say, is Synnovation that Novartis recently acquired for $2 billion. So that is the target we are going after. And boron chemistry brings uniqueness to binding in this space, and it also brings uniqueness in a very crowded space to freedom to operate.
So we are excited. So that just highlights some of the work. We have lots more going on before this. So lots to talk about. Just to wrap it up, there are multiple value inflection points, especially in our phase II proof of concept trials, starting with PV in early 2027 and throughout. Both the NTM project for abscessus and Chagas disease will come in late 2027 as proof of concept. All those are phase II big projects. Then we have our early compounds that will be going into the clinic at the end of 2027, so hypophosphatasia and et cetera. Anyway, lots of excitement for AN2.
I couldn't be more proud of this company and research team and what we've been able to do over the last few years to strengthen our pipeline and be in a position to really help patients forward and have significant value opportunity here. Thank you very much for your attention. I think we were going to do maybe a little QA. We got a couple of minutes, but if there are any questions. Otherwise, we'll wrap it up. Yes.
How do you see development of your abscessus program as you move towards pivotal? What would it all look like? Would you be running potentially against dealer's choice, or is there a potential to use an external control or something like that? Flexibility like that?
Yeah. Abscessus, we're running. The trial we're running is monotherapy. I think it's TBD. We just had an ad board with all of our advisors, and we're trying to look at different clinical trial designs. We'll have more information on that. It will be either in combination with other agents as an all-oral agent or potentially even with IV to shorten therapy duration if we can. That's in discussions now. Yeah. Okay. All right. Well, thank you very much.